TY - JOUR
T1 - Incidence and Outcomes of Hypertensive Phase Following Aurolab Aqueous Drainage Implant Surgery in Adults with Refractory Glaucoma
AU - Puthuran, George Varghese
AU - Wijesinghe, Hiruni Kaushalya
AU - Gedde, Steven J.
AU - Tara, Techi Dodum
AU - Uduman, Mohammed Sithiq
AU - Krishnadas, Subbaiah Ramasamy
AU - Lee Robin, Alan
AU - Palmberg, Paul
N1 - Funding Information:
Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Funding/Support: This study received no funding. Financial Disclosures: Alan Lee Robin is Executive Vice President, American Glaucoma Society, Consultant: Versant Health, Consultant: Perfuse Therapeutics. Paul Palmberg is a consultant and Medical Monitor for InnFocus, Inc, a Santen company, for the FDA trial of the MicroShunt. This includes hororaia and travel support for attending international meetings to present data from the US-Europe FDA trial of the MicroShunt, but has no stock options or equity in any specific company, and no intellectual property rights. He has also in the past year received honoraria and travel support for being an invited speaker at the Moroccan Ophthalmology Society, and UCLA-Doheny. None of those things are related to the submitted article. All authors attest that they meet the current ICMJE criteria for authorship. We acknowledge the inputs from Dr Sabyasachi Sengupta for statistical analysis.
Publisher Copyright:
© 2020 Elsevier Inc.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Purpose: To report the incidence and outcomes of hypertensive phase (HP) following Aurolab Aqueous Drainage Implant (AADI) (Aurolab) surgery in adults with refractory glaucoma. Design: Retrospective, noncomparative, interventional case series. Methods: All eyes that received the AADI and had a minimum of 2-year follow-up were identified, and data of patients who had intraocular pressure (IOP) ≤21 mm Hg at 6 weeks (ie, the time at which the tube-ligature suture dissolves) were used for statistical analysis. HP was defined as IOP >21 mm Hg during the first 3 months after the release of the tube ligating suture (with or without medications) in the absence of tube obstruction. Results: A total of 200 eyes were included in the study, and HP was seen in 64 eyes (32%) with a peak IOP (mean ± SD) of 29.6 ± 7.8 mm Hg and peak incidence at 2-3 months after surgery. HP resolved within 3 months of its onset in 60 of the 64 eyes (94%) with additional IOP-lowering medications. The cumulative success rates were 71.8% (95% CI = 59.3%-81.2%) in HP eyes and 76.4% (95% CI = 68.7%-82.7%) in non-HP eyes (P = .23). Unadjusted Cox proportional hazards analysis showed that eyes experiencing HP had a marginally higher risk of failure (HR = 1.16, 95% CI = 0.6-2.1), but this relationship was not statistically significant (P = .61). Conclusions: A third of eyes that underwent AADI placement experienced HP. HP was successfully managed with additional IOP-lowering medications in a majority of cases and did not have a significant influence on long-term success rate.
AB - Purpose: To report the incidence and outcomes of hypertensive phase (HP) following Aurolab Aqueous Drainage Implant (AADI) (Aurolab) surgery in adults with refractory glaucoma. Design: Retrospective, noncomparative, interventional case series. Methods: All eyes that received the AADI and had a minimum of 2-year follow-up were identified, and data of patients who had intraocular pressure (IOP) ≤21 mm Hg at 6 weeks (ie, the time at which the tube-ligature suture dissolves) were used for statistical analysis. HP was defined as IOP >21 mm Hg during the first 3 months after the release of the tube ligating suture (with or without medications) in the absence of tube obstruction. Results: A total of 200 eyes were included in the study, and HP was seen in 64 eyes (32%) with a peak IOP (mean ± SD) of 29.6 ± 7.8 mm Hg and peak incidence at 2-3 months after surgery. HP resolved within 3 months of its onset in 60 of the 64 eyes (94%) with additional IOP-lowering medications. The cumulative success rates were 71.8% (95% CI = 59.3%-81.2%) in HP eyes and 76.4% (95% CI = 68.7%-82.7%) in non-HP eyes (P = .23). Unadjusted Cox proportional hazards analysis showed that eyes experiencing HP had a marginally higher risk of failure (HR = 1.16, 95% CI = 0.6-2.1), but this relationship was not statistically significant (P = .61). Conclusions: A third of eyes that underwent AADI placement experienced HP. HP was successfully managed with additional IOP-lowering medications in a majority of cases and did not have a significant influence on long-term success rate.
UR - http://www.scopus.com/inward/record.url?scp=85095714862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095714862&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2020.08.026
DO - 10.1016/j.ajo.2020.08.026
M3 - Article
C2 - 32828879
AN - SCOPUS:85095714862
VL - 221
SP - 75
EP - 82
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
ER -